Maintenance of patient-reported health-related quality of life post neoadjuvant relugolix prior to the initiation of prostate radiation therapy
IntroductionStudies have demonstrated that injectable GnRH receptor agonists further suppress cancer progression when paired with radiotherapy (RT) in patients with intermediate- to high-risk prostate adenocarcinoma. Relugolix is a newly available oral GnRH receptor antagonist that achieves swift an...
Saved in:
Main Authors: | Min Jung Koh, Min Ji Koh, Jessica Y. Hsueh, Lindsey Gallagher, Malika Danner, Alan Zwart, Marilyn Ayoob, Deepak Kumar, Michael Carrasquilla, Paul Leger, Nancy A. Dawson, Simeng Suy, Sean P. Collins |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1496646/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer
by: Kelly Gaudian, et al.
Published: (2025-01-01) -
Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study
by: Giuseppe Salfi, et al.
Published: (2025-01-01) -
Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis
by: Amir Alinejad Khorram, et al.
Published: (2024-12-01) -
Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer
by: Maurizio Capuozzo, et al.
Published: (2024-05-01) -
Development of Novel Nomograms to Predict 5- and 7-Year Biochemical-Recurrence-Free Survival in High-Risk Prostate Cancer Patients After Carbon-Ion Radiotherapy and Androgen Deprivation Therapy
by: Takanobu Utsumi, et al.
Published: (2025-01-01)